Inst. Holders
50 funds
TERN
Terns Pharmaceuticals, Inc.
—
12-mo target$53.00 (+0.1%)
High Impact Filing (8/10)50 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TERN right now — valuation, ownership and activity at a glance.
Inst. Value
$4.4B
Inst. Activity
0 buys / 50 sells
Insider Activity
$0.00 buy / $730.8K sell
Insider Net $
-$730.8K
SEC Reports
6
Press Releases
2
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 3, 2026 earnings_calendar
TERN Q2 2026 Earnings Scheduled — 2026-08-03
Jun 30, 2026 Inst.
STATE STREET CORP — EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
May 15, 2026 SEC CITADEL ADVISORS LLC — EXIT
0 shares ($0.00)
Terns Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective May 15, 2026.
15-12G — Impact 8/10
Terns Pharmaceuticals' automatic shelf registration statement (S-3ASR) filed on December 9, 2025, became effective on Ma
EFFECT — Impact 4/10
Terns Pharmaceuticals has been acquired by Merck Sharp & Dohme in a completed all-cash merger. The tender offer expired
8-K — Impact 8/10
May 5, 2026 Insider
Burroughs Amy L. disposed of 146,614 shares
Chief Executive Officer @ $53.00 ($7.8M)
May 5, 2026 Insider
Burroughs Amy L. disposed of 150,000 shares
Chief Executive Officer @ $53.00 ($8.0M)
Analyst ratings buy % -62.8%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 27, 2026 | Oppenheimer | DOWNGRADE | Perform | 52% |
| Apr 14, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Mar 31, 2026 | Truist Securities | DOWNGRADE | Hold | 55% |
| Mar 30, 2026 | Barclays | DOWNGRADE | Equal-Weight | 54% |
| Mar 26, 2026 | Citizens | DOWNGRADE | Market Perform | 38% |
| Mar 26, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
| Mar 25, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Dec 11, 2025 | Citizens | MAINTAIN | Market Outperform | 38% |
| Dec 9, 2025 | Truist Securities | MAINTAIN | Buy | 55% |
| Dec 9, 2025 | Oppenheimer | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| Aug 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| Jul 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| Jun 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| May 1, 2026 | 2 | 4 | 11 | 0 | 0 | 35% | |
| Apr 1, 2026 | 5 | 4 | 8 | 0 | 0 | 53% | |
| Mar 1, 2026 | 6 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 5 | 11 | 1 | 0 | 0 | 94% |
Price targets
Where 4 covering analysts think TERN trades over the next 12 months.
$53.00 +0.1% upside Hold
Current$52.95 Low$53.00 Median$53.00 High$53.00 4 analysts
$53.00$53.00
Analyst rating Hold· 3.0/5 as of Jul 18, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 2 neutral · avg impact 7.0/10.Plus 2 press releases.
BEARISH15-12G8/10
Terns Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), eff
May 15, 2026
NEUTRALEFFECT4/10
Terns Pharmaceuticals' automatic shelf registration statement (S-3ASR) filed on December 9, 2025, be
May 8, 2026
NEUTRAL8-K8/10
Terns Pharmaceuticals has been acquired by Merck Sharp & Dohme in a completed all-cash merger. The t
May 5, 2026
BEARISH25-NSE9/10
Nasdaq filed a Form 25-NSE to delist Terns Pharmaceuticals (TERN) common stock, effective immediatel
May 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 3, 2026
earnings_calendar
TERN Q2 2026 Earnings Scheduled — 2026-08-03
May 18, 2026
earnings_calendar
TERN Q1 2026 Earnings Scheduled — 2026-05-18
May 6, 2026
earnings_calendar
TERN Q1 2026 Earnings Scheduled — 2026-05-06
Apr 29, 2026
short_interest
FTD: TERN — 22,564 shares ($1.2M) failed to deliver
Settlement: 20260429, Price: $52.94, FTD Value: $1,194,538.16, TERNS PHARMACEUTICALS INC COM
Apr 27, 2026
fda
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) wit
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Next Q | $-0.28 | $-0.34–$-0.24 | -6.4% | +3.3% | 3↑ 1↓ | $0.0B | 3 |
| Current FY | $-1.24 | $-1.48–$-1.00 | -20.4% | -16.8% | 3↑ 1↓ | $0.0B | 2 |
| Current Q | $-0.26 | $-0.32–$-0.22 | -1.3% | +2.9% | 2↑ 1↓ | $0.0B | 3 |
| Next FY | $-1.56 | $-1.82–$-1.29 | -25.5% | -5.7% | 2↑ 1↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.263 | — |
| 7d ago | $-0.271 | +0.008 |
| 30d ago | $-0.271 | +0.008 |
| 60d ago | $-0.287 | +0.024 |
| 90d ago | $-0.303 | +0.040 |
Institutional ownership
Which big funds own TERN (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $4.4B total value (83,967,866 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, MORGAN.
Top holders — 2026-Q1
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 9,569,585 | $504.5M | 11.4% | EXIT -100.0% |
| MORGAN STANLEY | 6,449,140 | $340.0M | 7.7% | EXIT -100.0% |
| Avoro Capital Advisors LLC | 5,695,000 | $300.2M | 6.8% | EXIT -100.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,355,482 | $229.6M | 5.2% | EXIT -100.0% |
| Holocene Advisors, LP | 4,115,828 | $217.0M | 4.9% | EXIT -100.0% |
| CITADEL ADVISORS LLC | 3,218,810 | $169.7M | 3.8% | EXIT -100.0% |
| MILLENNIUM MANAGEMENT LLC | 3,011,558 | $158.8M | 3.6% | EXIT -100.0% |
| HBK INVESTMENTS L P | 2,950,000 | $155.5M | 3.5% | — |
| JPMORGAN CHASE & CO | 2,869,728 | $151.8M | 3.4% | EXIT -100.0% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| STATE STREET CORP | EXIT | 2,139,662 | 0 | -100.0% | $0.00 |
| CITADEL ADVISORS LLC | EXIT | 3,218,810 | 0 | -100.0% | $0.00 |
| Magnetar Financial LLC | EXIT | 281,614 | 0 | -100.0% | $0.00 |
| Avoro Capital Advisors LLC | EXIT | 5,695,000 | 0 | -100.0% | $0.00 |
| Sculptor Capital LP | EXIT | 380,000 | 0 | -100.0% | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | 2,316,544 | 0 | -100.0% | $0.00 |
| JPMORGAN CHASE & CO | EXIT | 2,869,728 | 0 | -100.0% | $0.00 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | 1,247,845 | 0 | -100.0% | $0.00 |
| Capital International Investors | EXIT | 1,424,504 | 0 | -100.0% | $0.00 |
| FMR LLC | EXIT | 295,622 | 0 | -100.0% | $0.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 48 transactions. Net -$730.8K — $0.00 bought, $730.8K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 5, 2026 | Burroughs Amy L. | Chief Executive Officer | U | 146,614 | $53.00 | $7.8M |
| May 5, 2026 | Burroughs Amy L. | Chief Executive Officer | D | 150,000 | $53.00 | $8.0M |
| May 5, 2026 | Burroughs Amy L. | Chief Executive Officer | D | 955,534 | — | — |
| May 5, 2026 | Gengos Andrew | Chief Financial Officer | U | 40,503 | $53.00 | $2.1M |
| May 5, 2026 | Gengos Andrew | Chief Financial Officer | D | 68,750 | $53.00 | $3.6M |
| May 5, 2026 | Gengos Andrew | Chief Financial Officer | D | 750,000 | — | — |
| May 5, 2026 | Kuriakose Emil | Chief Medical Officer | U | 24,562 | $53.00 | $1.3M |
| May 5, 2026 | Kuriakose Emil | Chief Medical Officer | D | 81,953 | $53.00 | $4.3M |
| May 5, 2026 | Kuriakose Emil | Chief Medical Officer | D | 485,000 | — | — |
| May 5, 2026 | KINDLER JEFFREY B | Director | D | 32,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TERN.
Shares short
5,535,964
Settlement Apr 30, 2026
Change vs prior
-31.3%
Semi-monthly cycle
Days to cover
1.5
At avg daily volume
All TERN filing & press-release reports (8)
- 15-12G reportMay 15, 2026
- EFFECT reportMay 8, 2026
- 8-K reportMay 5, 2026
- 25-NSE reportMay 5, 2026
- 8-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportMar 25, 2026
- INST-CLUSTER reportFeb 28, 2026